ERBB2 and neoplasm: To rigorously evaluate the possible mechanism of romidepsin anti-tumor activity, we stably transformed NIH 3T3 mouse fibroblasts and RIE-1 epithelial cells with the oncogenic forms of H-, K-, and N-Ras, as well as with oncogenic B-Raf and ErbB2/Neu.